Grupo para la caracterización molecular de las neoplasias hematológicas
Hospital de Jerez
Jerez, EspañaPublicaciones en colaboración con investigadores/as de Hospital de Jerez (35)
2022
-
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis
British Journal of Haematology, Vol. 199, Núm. 4, pp. 529-538
-
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
Cancer, Vol. 128, Núm. 13, pp. 2441-2448
2021
-
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group
Leukemia and Lymphoma, Vol. 62, Núm. 12, pp. 2928-2938
-
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
Blood Cancer Journal, Vol. 11, Núm. 5
2020
-
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis
Medicina Clinica, Vol. 155, Núm. 4, pp. 152-158
2018
-
Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment
Hematological Oncology, Vol. 36, Núm. 5, pp. 765-772
-
Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia
British Journal of Haematology
-
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy
Leukemia, Vol. 32, Núm. 1, pp. 21-29
-
Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis
Leukemia
-
Prognostic risk models for transplant decision-making in myelofibrosis
Annals of Hematology, Vol. 97, Núm. 5, pp. 813-820
-
Wilms Tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology
British Journal of Haematology
2017
-
Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure
Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 10, pp. 1631-1640
-
Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia
British Journal of Cancer, Vol. 117, Núm. 2, pp. 256-265
-
Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma
Cancer Medicine, Vol. 6, Núm. 12, pp. 2766-2774
-
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
Haematologica, Vol. 102, Núm. 1, pp. 103-109
2016
-
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis
Blood, Vol. 127, Núm. 9, pp. 1151-1162
2014
-
Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?
American Journal of Hematology, Vol. 89, Núm. 11, pp. E206-E211
2011
-
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens
Blood, Vol. 117, Núm. 6, pp. 1799-1805